Latest Leverage News

Aspermont Limited reported a $1.49 million net cash outflow in Q1 FY26 but maintains its forecast to become cash generative by Q3, supported by strong trading performance and strategic progress.

Yowie Group has landed a three-year seasonal licence to produce and distribute beloved Australian confectionery brands Violet Crumble, Polly Waffle, and FruChocs across Australia and New Zealand, targeting $6.5 million in net sales.

Adelong Gold has finalised the sale of its remaining 49% interest in Challenger Mines to Great Divide Mining, receiving 10 million GDM shares and retaining a capped royalty on future gold production.

Bellavista Resources Ltd has agreed to acquire a majority stake in the high-grade Pickle Crow Gold Project in Ontario, Canada, boasting a 2.8 million ounce inferred resource at 7.2g/t gold. The company is also raising up to A$25 million to fund aggressive exploration and development.

Mamba Exploration Limited has agreed to acquire a 70% interest in the Meeka East Gold Project in Western Australia’s Murchison Goldfield, supported by a $2 million capital raise to fund exploration activities.

Actinogen Medical has raised approximately $17 million through a share placement and purchase plan to fund the completion of its pivotal XanaMIA Alzheimer’s trial following encouraging interim results.

First Au Limited has successfully raised $5.6 million in a placement to fund exploration at its Gimlet Gold Project and expand its Western Australian gold strategy.

FireFly Metals has agreed to sell its Ontario gold assets to Bellavista Resources for up to A$86.1 million in shares and performance rights, unlocking value for shareholders while focusing on its copper-gold growth strategy.

Cyprium Metals has completed the first tranche of a A$36 million placement, positioning itself to fast-track exploration and production growth at its Nifty Copper Complex in Western Australia.

PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.

Cyclopharm has reported a record $32.3 million in operating revenue for FY2025, led by explosive growth in its U.S. Technegas market following FDA approval. The company reaffirms its ambitious target of 250–300 U.S. installations by mid-2026 amid strong clinical momentum.

FortifAI Limited has completed its acquisition of FastAI Pty Ltd, gaining control of the innovative Nol8 technology and appointing seasoned executive Yosef Keret as director and Celerriem CEO.